This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00059722

Purpose

The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

Condition	Intervention	Phase
Carcinoma, Non-Small-Cell Lung	Drug: ZD6474 Drug: Placebo Drug: ZD1839	Phase II

MedlinePlus related topics: Cancer

Drug Information available for: ZD1839 Vandetanib

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Dose Comparison, Crossover Assignment, Efficacy Study
Official Title:	A Phase II, Randomized Double-Blind, 2-Part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-Small Cell Lung Cancer After Failure of First-Line Platinum-Based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Primary Outcomes:
Part A
i. Time to progression
ii. Incidence, CTC grade and type of Aes, clinicallyl significant laboratory abnormalities or changes in vital signs, and ECG changes
Part B

Secondary Outcome Measures:

Secondary Outcomes:
Part A
i. Objective response
ii. Disease control at 8 weeks
iii. Time to death
iv. WHO performance status
v. QOL and LCS from the FACT-L questionnaire
Part B
i. Objective response in subjects following treatment with the alternate study treatment
ii. Disease control at 8 weeks in subjects following treatment with the alternate study treatment
iii. WHO performance status in subjects following treatment with the alternate study treatment
iv. QOL and LCS from the FACT-L questionnaire in subjects following treatment with the alternate study treatment

Estimated Enrollment:	160
Study Start Date:	April 2005

Eligibility

Criteria

Inclusion Criteria:

Failure of either first-line and/or second-line chemotherapy either of which was platinum-based (the prior regimen must have failed the subject because of toxicity or progression of tumor
Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV) NSCLC

Exclusion Criteria:

Subjects who have received second-line or subsequent chemotherapy
Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic, need not be excluded)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00059722

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca Oncology Medical Director, MD

AstraZeneca

More Information

Study ID Numbers:	6474IL/0003
Study First Received:	May 2, 2003
Last Updated:	October 5, 2005
ClinicalTrials.gov Identifier:	NCT00059722
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

NSCLC
locally advanced or metastatic
second-line

Study placed in the following topic categories:

Thoracic Neoplasms
Non-small cell lung cancer
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases

Gefitinib
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors
Protein Kinase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009